



Published in final edited form as:

*Circulation*. 2019 February 26; 139(9): 1162–1173. doi:10.1161/CIRCULATIONAHA.118.037425.

## Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis: Analysis from a Stratified Multicenter Randomized Trial

Anthony J. Comerota, M.D.<sup>1</sup>, Clive Kearon, M.B, Ph.D.<sup>2,3</sup>, Chu-Shu Gu, Ph.D.<sup>3,4</sup>, Jim A. Julian, M.Math<sup>3,4</sup>, Samuel Z. Goldhaber, M.D.<sup>5</sup>, Susan R. Kahn, M.D., M.Sc.<sup>6</sup>, Michael R. Jaff, D.O.<sup>7</sup>, Mahmood K. Razavi, M.D.<sup>8</sup>, Andrei L. Kindzelski, M.D., Ph.D.<sup>9</sup>, Riyaz Bashir, M.D.<sup>10</sup>, Parag Patel, M.D.<sup>11</sup>, Mel Sharafuddin, M.D.<sup>12</sup>, Michael J. Sichelau, M.D.<sup>13</sup>, Wael E. Saad, M.D.<sup>14</sup>, Zakaria Assi, M.D.<sup>15</sup>, Lawrence V. Hofmann, M.D.<sup>16</sup>, Margaret Kennedy, M.D., M.Sc.<sup>17</sup>, Suresh Vedantham, M.D.<sup>18</sup>, and ATTRACT Trial Investigators

<sup>1</sup>Inova Heart and Vascular Institute, Inova Alexandria Hospital, Alexandria, VA, United States

<sup>2</sup>McMaster University, Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada

<sup>3</sup>Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

<sup>4</sup>McMaster University, Department of Oncology, Hamilton, ON, Canada

<sup>5</sup>Brigham and Women's Hospital, Division of Cardiovascular Medicine, and Harvard Medical School, Boston, MA, United States

<sup>6</sup>Jewish General Hospital, Lady Davis Institute, Center for Clinical Epidemiology, Montreal, QC, Canada

<sup>7</sup>Newton-Wellesley Hospital, Newtown, and Harvard Medical School, Boston, MA, United States

<sup>8</sup>St. Joseph's Hospital, Orange, CA, United States

---

Corresponding Author: Suresh Vedantham, M.D., Professor of Radiology & Surgery, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway, Box 8131, St. Louis, MO 63110, Phone: (314) 362-2900, Fax: (314) 362-2276, vedanthams@mir.wustl.edu.

### DISCLOSURES (in order of authorship)

Anthony J. Comerota: Consulting fees from Medtronic.

Clive Kearon: None

Chu-Shu Gu: None

Jim A. Julian: None

Samuel Z. Goldhaber: Grant support from BiO2 Medical, and grant support and consulting fees from Boehringer Ingelheim, BMS, Daiichi Sankyo, Janssen, Portola, Bayer, BTG/Ekos

Susan R. Kahn: Advisory board fees from BMS Pfizer, Sanofi, and Aspen.

Michael R. Jaff: Holds equity in Embolitech and Venarum: uncompensated advisor, Boston

Scientific, Cordis Corporation, and Medtronic; consultant, Volcano/Phillips

Mahmood K. Razavi: Consultant for Abbott, Boston Scientific, Medtronic, Veniti, Volcano/Phillips

Andrei L. Kindzelski: None

Riyaz Bashir: Equity holder and co-founder, Thrombolex, Inc.

Parag Patel: Speaking fees from Boston Scientific

Mel Sharafuddin: None

Michael J. Sichelau: None

Wael E. Saad: Consultant and speaker for Siemens and Gore

Zakaria Assi: None

Lawrence V. Hofmann: Consultant and Royalties from Cook Medical

Margaret Kennedy: None

Suresh Vedantham: Research support from Cook Medical

<sup>9</sup>National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States

<sup>10</sup>Temple University Hospital, Department of Medicine, Philadelphia, PA, United States

<sup>11</sup>Medical College of Wisconsin, Department of Radiology, Milwaukee, WI, United States

<sup>12</sup>University of Iowa, Division of Vascular Surgery, Iowa City, IA, United States

<sup>13</sup>Vascular and Interventional Professionals, LLC, Hinsdale, IL, United States

<sup>14</sup>University of Michigan, Department of Radiology, Ann Arbor, MI, United States

<sup>15</sup>Toledo Radiological Associates, Vascular & Interventional Radiology, Toledo, OH, United States

<sup>16</sup>Stanford University, Department of Radiology, Stanford, CA, United States

<sup>17</sup>Duke University, Department of Medicine, Durham, NC, United States

<sup>18</sup>Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, United States

## Abstract

**Background:** The ATTRACT Trial previously reported that pharmacomechanical catheter-directed thrombolysis (PCDT) did not prevent the post-thrombotic syndrome (PTS) in patients with acute proximal deep vein thrombosis (DVT). In the current analysis, we examine the effect of PCDT in ATTRACT patients with iliofemoral DVT.

**Methods:** Within a large multicenter randomized trial, 391 patients with acute DVT involving the iliac and/or common femoral veins were randomized to PCDT with anticoagulation versus anticoagulation alone (No-PCDT) and were followed for 24 months to compare short-term and long-term outcomes.

**Results:** Between 6 and 24 months, there was no difference in the occurrence of PTS (Villalta scale 5 or ulcer: 49% PCDT versus 51% No-PCDT; risk ratio (RR)=0.95; 95% confidence interval (CI), 0.78–1.15; p=0.59). PCDT led to reduced PTS severity as shown by: lower mean Villalta and Venous Clinical Severity Scores [VCSS] (p<0.01 for comparisons at 6, 12, 18, and 24 months); and fewer patients with moderate-or-severe PTS (Villalta scale 10 or ulcer: 18% versus 28%; RR 0.65; 95% CI 0.45–0.94, p=0.021) or severe PTS (Villalta scale 15 or ulcer: 8.7% versus 15%; RR 0.57; 95% CI 0.32–1.01, p=0.048; and VCSS 8: 6.6% versus 14%; RR 0.46; 95% CI 0.24–0.87, p=0.013). From baseline, PCDT led to greater reduction in leg pain and swelling (p<0.01 for comparisons at 10 and 30 days) and greater improvement in venous disease-specific QOL (VEINES-QOL unit difference 5.6 through 24 months, p=0.029), but no difference in generic QOL (p > 0.2 for comparisons of SF-36 mental and physical component summary scores through 24 months). In patients having PCDT versus No-PCDT, major bleeding within 10 days occurred in 1.5% versus 0.5% (p=0.32), and recurrent VTE over 24 months was observed in 13% versus 9.2% (p=0.21).

**Conclusions:** In patients with acute iliofemoral DVT, PCDT did not influence the occurrence of PTS or recurrent VTE. However, PCDT significantly reduced early leg symptoms and, over 24

months, reduced PTS severity scores, reduced the proportion of patients who developed moderate-or-severe PTS, and resulted in greater improvement in venous disease-specific QOL.

**Clinical Trial Registration:** [www.clinicaltrials.gov](http://www.clinicaltrials.gov); NCT00790335

### Keywords

deep vein thrombosis; iliofemoral; thrombolysis; post-thrombotic syndrome

---

## INTRODUCTION

Iliofemoral deep vein thrombosis (DVT), defined as DVT that involves the iliac and/or common femoral vein (with or without involvement of additional veins), often causes functional obstruction of venous outflow of the involved leg (1,2). These patients are phenotypically distinct from patients with calf or femoral-popliteal DVT, based on more frequent recurrent venous thromboembolic events, more frequent post-thrombotic syndrome (PTS), and more severe PTS (1,3-7). Preliminary studies of catheter-directed thrombolysis and related methods have suggested that these strategies may be most useful in patients with iliofemoral DVT compared to those with less extensive proximal DVT, and that the occurrence and degree of thrombus clearance may correlate with clinical outcome (8-13).

The biological plausibility that iliofemoral DVT should be recognized as a distinct entity in the anatomic spectrum of acute DVT is rooted in the anatomy and physiology of lower extremity venous return and the observation that venous recanalization occurs less often in patients with iliofemoral versus more distal DVT who were treated with anticoagulation alone or systemic thrombolysis (14,15). As the entire volume of venous blood return is directed through the common femoral and iliac veins, obstruction of this channel results in marked post-thrombotic venous hypertension (16) and severe post-thrombotic morbidity (3-7).

The main results of the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) Trial, the largest randomized trial evaluating catheter based intervention for acute proximal DVT, were recently reported (17,18). This study found no reduction of 2-year PTS frequency (the study's primary outcome) or improvement in health-related quality of life (QOL) in patients treated with pharmacomechanical catheter-directed thrombolysis (PCDT) compared with those treated with anticoagulation alone, although there was a reduction in the severity of PTS in the PCDT-treated group. Importantly, patients in this study were stratified by the most proximal extent of their DVT (iliofemoral versus femoral-popliteal) prior to randomization, permitting a valid analysis of the outcomes of these two distinct anatomic-clinical presentations. The purpose of this analysis is to report the benefits and risks of PCDT in the patients in the ATTRACT Trial who presented with acute iliofemoral DVT.

## METHODS

### Study Organization

The study design and the main study results for the overall ATTRACT cohort have been previously described (17,18). In brief, this was a NIH-sponsored, Phase III, multicenter, randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial ([www.attract.wustl.edu](http://www.attract.wustl.edu); NCT00790335). All patients provided written informed consent. The study was approved by the Institutional Review Boards at all participating centers. The authors and Steering Committee are solely responsible for the design and conduct of the study, all analyses, and the writing of this article. The data and study materials will be made available to other researchers in accordance with the NIH Public Access Policy, at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or by contacting the Corresponding Author.

### Patient Population, Stratification, and Randomization

Patients presenting with DVT in the femoral or a more proximal vein with symptoms of 14 days or less were enrolled from 56 centers in the United States (U.S.). Patients were stratified by clinical center and by the most proximal extent of their DVT, that is, whether the DVT involved the iliac and/or common femoral vein (“iliofemoral DVT”; this term applied whether or not more caudal veins were also involved), or not (“femoral-popliteal DVT”) (1,2). After stratification, patients were randomized in a 1:1 ratio to receive either PCDT with anticoagulation (PCDT Arm), or anticoagulation alone (No-PCDT Arm), and followed for 2 years. In this analysis, we report exclusively on the 391 patients with iliofemoral DVT; the patients with femoral-popliteal DVT are reported elsewhere.

### Treatments

All patients were treated with initial and long-term anticoagulation consistent with published guidelines (19,20), and were provided knee-high 30 – 40 mm Hg ankle gradient elastic compression stockings (BSN Medical, Charlotte, NC) at their 10 day follow-up visit and every 6 months.

PCDT was performed as described elsewhere by board-certified physicians whose credentials were approved by the trial leadership, using methods consistent with published guidelines (21,22). Recombinant tissue plasminogen activator (rt-PA) (alteplase, Activase<sup>®</sup>, Genentech, South San Francisco, CA) was infused into the thrombus using one of three methods: a standard multi-sidehole catheter (“infusion-first”); the AngioJet Rheolytic Thrombectomy System (Boston Scientific, Malborough, MA) (“power pulse-spray” or “rapid lysis” method); or the Trellis Peripheral Infusion System (Covidien, Inc., Mansfield, MA [now Medtronic], “isolated thrombolysis”). Rt-PA dosing limits were: 1) 0.01 mg/kg/hr, not to exceed 1.0 mg/hr; 2) no more than 30 hours infusion; 3) no more than 25 mg in any one procedure session; and 4) no more than 35 mg total. After initial rt-PA delivery, physicians could use balloon maceration, catheter aspiration, thrombectomy devices, and/or balloon angioplasty to clear residual thrombus. Stent placement was encouraged for obstructive lesions in the iliac vein and/or common femoral vein causing 50% diameter narrowing, > 2 mmHg mean pressure gradient, or robust collateral filling on venography.

Patients received heparin-based anticoagulation during PCDT, as previously described (17,18).

### Outcome Assessments

Patient outcomes were assessed at 10 and 30 days, and at 6, 12, 18, and 24 months following randomization, by clinicians who were blinded to treatment allocation. The adjudicators of safety and efficacy outcomes were also unaware of the treatment assignments.

PTS, defined as a Villalta score of  $\geq 5$  or a venous ulcer in the leg with the index DVT that occurred at any one or more assessments between the 6 month and 24 month follow-up visits (inclusive), was the study's primary efficacy outcome (23,24). The Villalta scale rates the severity of five patient-reported symptoms (pain, cramps, heaviness, pruritus, paresthesia) and six clinician-observed signs (edema, skin induration, hyperpigmentation, venous ectasia, redness), with each item scored from 0-3. Points for symptoms and signs are summed into a total score (range 0-33), and patients can be categorized as having no PTS (score 0-4), mild PTS (score 5-9), moderate PTS (score 10-14) or severe PTS (score  $\geq 15$ , or presence of ulcer). Development of PTS was also attributed to patients if they underwent an unplanned endovascular procedure to treat severe venous symptoms beyond 6 months after randomization, unless there was a Villalta score  $< 5$  in the previous 4 weeks.

The severity of PTS was evaluated at 6, 12, 18, and 24 months using the Villalta score and the Venous Clinical Severity Score (VCSS) (25) as continuous measurements. In addition, using the Villalta score, the presence of moderate or severe PTS (Villalta score  $\geq 10$ , or an ulcer), or severe PTS (Villalta score  $\geq 15$ , or an ulcer) were assessed as secondary outcomes. Using the VCSS (ranges from 0 to 27, with higher scores indicating more severe PTS), the presence of PTS (VCSS score  $\geq 4$ ) and severe PTS (VCSS score  $\geq 8$ ) were also assessed using previously published criteria (26).

Generic health-related quality of life (QOL) was assessed with the SF-36 Health Status Survey (27), and venous disease-specific QOL was assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) measure (28).

Leg pain and leg swelling were assessed at baseline, 10 days, and 30 days using a 7-point Likert pain scale and by measuring calf circumference (29).

Patients receiving PCDT had the amount of thrombus removal quantified by independent central readers using the proximal-vein components of the Marder score (30).

Safety outcomes included bleeding, recurrent venous thromboembolism, and death, which were recorded throughout follow-up and summarized through 10 days and 24 months. Clinically overt bleeding was classified as "major" if it was associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of  $\geq 2$  units of red blood cells, or involvement of a critical site (e.g., intracranial, intraspinal) (31). Less severe clinically overt bleeding was classified as "minor".

## Sample Size

Sample size for the entire ATTRACT study was 692 proximal DVT patients based on these assumptions: 30% of control patients would develop PTS between 6 and 24 months; PCDT would reduce PTS by at least 33%; 10% loss to follow-up; need to have 80% power to detect the hypothesized treatment effect; acceptance of a two-side  $\alpha$  error of 0.05. We did not estimate the sample size for the iliofemoral DVT subgroup, pre-specify the proportion of patients expected to have iliofemoral DVT, or require a minimum number of patients with iliofemoral DVT. A sample size of 391, corresponding to the number of patients in the current analysis, provides approximately 80% power to detect (i) a 41% PTS reduction assuming a control proportion of 30%, and (ii) an effect size (i.e. mean difference divided by the SD) of at least 0.28, assuming a two-sided  $\alpha$  error of 0.05 with each type of analysis.

## Statistical Analysis

Two types of analyses were performed: a modified intention-to-treat analysis (primary analysis) that included all randomized patients except those who did not have DVT at enrollment; and a per-protocol analysis (secondary analyses) that excluded patients who, within 7 days post-randomization, were randomized to PCDT but did not receive it, or who were randomized to control but had skin puncture for PCDT thrombolysis or any thrombolytic therapy.

Cumulative proportions were compared using the Cochran-Mantel-Haenszel test adjusted for clinical center. Treatment effects are summarized using stratum-adjusted risk ratios (RR) with their corresponding 95% confidence intervals (CI).

The mean Villalta, VCSS, and QOL assessments at each visit were estimated using piecewise linear regression growth curve models adjusting for clinical center and pre-specified baseline covariates (age, sex, body-mass index, race). Changes from baseline to 10 days and from baseline to 30 days for leg pain scores and calf circumferences in the index leg were compared using multiple linear regression, adjusted for clinical center. A supportive analysis modeled the values at 10 days and 30 days with the baseline value as a covariate. For the binary outcomes, interaction tests for subgroups were conducted using a logistic model with treatment, subgroup, and an interaction term as factors, with interaction p-values calculated using Wald joint tests. The risk ratios and 99% confidence intervals derived from the models were used to create the forest plots.

The analyses in this report are considered exploratory because, although they were pre-specified, they are confined to a subgroup of the main trial.

## RESULTS

### Baseline Characteristics of Participants

Of the 692 patients in ATTRACT, 391 (57%) had iliofemoral DVT of whom 196 were randomized to PCDT and 195 were randomized to No-PCDT (Figure 1). Median age was 52 years, 53% were male, the index DVT was in the left leg in 64%, and symptoms were



present for a median of 6 days (Table 1). Baseline characteristics were well balanced between the two treatment groups (Table 1)

### Protocol and Treatment Adherence

Within 7 days after randomization, 4 patients assigned to No-PCDT had PCDT, and 6 patients assigned to PCDT did not have the procedure (Figure 1). These patients were excluded from the per-protocol analysis. PCDT was performed at a median one day post-randomization. Initial anticoagulant therapy, which was usually low molecular weight heparin or unfractionated heparin, was similar in the PCDT and No-PCDT patients (Table 2). The initial rt-PA delivery method in PCDT Arm patients was the “infusion first” method in 52% (median total rt-PA dose of 21 mg), the AngioJet method in 24% (median total rt-PA dose of 21 mg), and the Trellis method in 19% (median total rt-PA dose of 20 mg) (PCDT not performed in 5%; Table 2). After initial rt-PA delivery, additional endovascular methods were used in 91% of patients, as summarized in Table 2. Mean thrombus removal as assessed by pre and post PCDT venography was 86% (mean pre-procedure and post-procedure Marder scores 12.0 and 3.0, respectively, change  $-9.1$ ; 95% CI,  $-8.2$  to  $-10.0$ ;  $p < 0.001$ ). The mean duration of anticoagulation before first permanent cessation during follow-up, use of antiplatelet therapy, and use of compression stockings were similar in the PCDT and No-PCDT patients (Table 2).

### Development of Post-Thrombotic Syndrome

In the intention-to-treat analysis using the study’s primary outcome measure (Villalta scale), PTS developed in 96 of 196 (49%) PCDT Arm patients and in 100 of 195 (51%) No-PCDT Arm patients (RR=0.95; 95% CI, 0.78-1.15;  $p=0.59$ ) during 24 months follow-up (Table 3). In the per-protocol analysis and in all subgroups evaluated, the findings were similar (Figure 2, Supplemental Table 1). Using the VCSS scale, PTS developed in 30% of PCDT Arm patients and in 40% of No-PCDT Arm patients (RR=0.75; 95% CI, 0.57-0.98;  $p=0.034$ ) (Table 3). In the per-protocol analysis, these findings were similar (29% PCDT versus 41% No-PCDT, RR=0.71, 95% CI, 0.54-0.94,  $p=0.015$ ) (Supplemental Table 1).

### Severity of Post-Thrombotic Syndrome

At 6, 12, 18, and 24 months, mean Villalta and VCSS scores were significantly lower in the PCDT Arm compared with the No-PCDT Arm ( $p < 0.01$  at all time-points, both analysis sets) (Table 4, Figure 3) (32).

Moderate-or-severe PTS, as assessed by a Villalta scale score  $\geq 10$  or ulceration, developed in 36 (18%) patients assigned to PCDT and in 55 (28%) patients assigned to No-PCDT (RR=0.65; 95% CI, 0.45 to 0.94;  $p=0.021$ ) (Table 3). The findings were similar in a per-protocol analysis (RR=0.63,  $p=0.013$ ) (Supplemental Table 1). For this outcome, patients’ sex, race, symptom duration (0-1 versus 1-2 weeks), side of DVT, and baseline symptom severity did not influence the effect of PCDT. However, patients  $< 65$  versus  $\geq 65$  years old ( $p$ -interaction=0.04) and those with versus without a major reversible DVT risk factor at diagnosis ( $p$ -interaction=0.05) appeared less likely to develop moderate-or-severe PTS with use of PCDT (Figure 4).

Severe PTS, as assessed by a Villalta score  $\geq 15$  or ulceration, developed in 17 (8.7%) patients assigned to PCDT and in 30 (15%) patients assigned to No-PCDT (RR=0.57; 95% CI, 0.32 to 1.01;  $p=0.048$ ) (Table 3). Severe PTS, as assessed by a VCSS score  $\geq 8$ , developed in 13 (6.6%) patients assigned to PCDT and 28 (14%) patients assigned to No-PCDT (RR=0.46; 95% CI, 0.24 to 0.87;  $p=0.013$ ) (Table 3). These findings were similar in per-protocol analyses (Supplemental Table 1). Ulceration developed in 9 (4.6%) patients assigned to PCDT and in 12 (6.2%) patients assigned to No-PCDT (RR=0.75; 95% CI, 0.32 to 1.73,  $p=0.49$ ).

### Change in Presenting Symptoms and Health-Related Quality of Life

Mean change in leg pain from baseline for PCDT versus No PCDT was  $-1.76$  versus  $-1.25$  Likert points at 10 days ( $p=0.009$ ), and  $-2.36$  versus  $-1.80$  Likert points at 30 days ( $p=0.008$ ) (Table 4). Mean change in calf circumference from baseline for PCDT versus No PCDT was  $-0.79$  cm versus  $+0.22$  cm at 10 days ( $p=0.002$ ) and  $-1.37$  cm versus  $-0.10$  cm at 30 days ( $p<0.001$ ). The findings for these outcomes were similar in the per-protocol analyses (Supplemental Table 2).

Mean change in venous disease-specific quality of life from baseline to 24 months was 28.6 versus 23.0 VEINES-QOL scale units in the PCDT versus No-PCDT Arms (between-group difference 5.6 units,  $p=0.029$ ). In the per-protocol analysis, this between-group difference was 5.3 units ( $p=0.04$ ).

Mean change in the symptoms component of venous disease-specific quality of life from baseline to 24 months was 21.5 versus 16.2 VEINES-Sym scale units in the PCDT versus No-PCDT Arms (between-group difference 5.2 points,  $p=0.043$ ). In the per-protocol analysis, this between-group difference was 5.1 units,  $p=0.012$ .

Mean change in generic quality of life (physical and mental component summary scores of SF-36 measure) from baseline to 24 months did not differ for the PCDT versus No-PCDT patients in either the intention-to-treat or per-protocol analyses ( $p>0.25$  for all analyses, Table 4, Supplemental Table 2).

### Safety Outcomes

Within 10 days, in PCDT versus No-PCDT patients, major bleeding occurred in three patients (1.5%) versus one patient (0.5%) ( $p=0.32$ ), and any bleeding occurred in seven (3.6%) versus four (2.1%) patients ( $p=0.36$ ) (Table 3). There were no fatal or intracranial bleeds. Recurrent venous thromboembolism within 24 months occurred in 26 (13.3%) PCDT versus 18 (9.2%) No-PCDT patients ( $p=0.21$ ) (none were fatal). Of the six deaths in each group, none occurred within 10 days post-randomization (Table 3). Per-protocol analyses of the safety outcomes were similar (Supplemental Table 1).

## DISCUSSION

Contemporary clinical practice guidelines (including a Scientific Statement from the American Heart Association) recommend that studies of DVT therapy report outcomes separately for patients with iliofemoral versus less extensive DVT (1,2). These and other



guidelines (19,20,22) also identify thrombus extent as a key factor to consider when deciding which patients should receive endovascular thrombus removal, which accounts for why some randomized trials have evaluated endovascular DVT therapies exclusively in patients with iliofemoral DVT (33-35). Consequently, this report focuses on findings in the iliofemoral DVT subgroup of the ATTRACT study.

Several studies have described favorable outcomes for aggressive thrombus removal therapies in comparison to anticoagulation alone in iliofemoral DVT, but each had major methodological limitations that undermine confidence in their findings. A small randomized trial evaluating surgical venous thrombectomy for acute iliofemoral DVT versus anticoagulation alone reported improved long term iliofemoral patency and reduced post-thrombotic morbidity in the surgically-treated patients (36). A post-hoc analysis of data from a prospective multicenter registry found that 68 CDT-treated patients had significantly fewer PTS symptoms, better physical functioning, less stigmata of chronic venous insufficiency, and less health distress ( $p < 0.05$  for all outcomes) at a mean follow-up of 16 months compared with 30 retrospectively “matched” patients who were treated with anticoagulation alone (9). A prospective non-randomized study ( $n=51$ ) found better 6-month and 5-year venous patency and freedom from venous symptoms in patients who received CDT versus anticoagulation alone (37). Finally, a single-center randomized trial comparing streptokinase CDT versus anticoagulation alone observed a higher rate of normal venous function and less valvular reflux in CDT recipients (38). However, these studies were limited by potential selection bias and baseline differences between treatment groups due to their non-randomized design (9,37), small sample size (9,36-38), performance in a single center (37,38), and lack of rigorous PTS assessment with validated tools (38).

A recent multicenter randomized trial that evaluated CDT for proximal DVT above mid-thigh level (the CAVENT Trial) found that CDT reduced PTS, which significantly correlated with patency of the ipsilateral iliofemoral venous segment (11,13). Since CAVENT did not report outcomes separately for iliofemoral DVT and femoral-popliteal DVT patients, we are unable to combine data from the iliofemoral subgroups of the two trials. Although in the total study population, CAVENT reported that CDT reduced any PTS, CDT did not improve long-term QOL and was associated with major and non-major bleeding complications. Consequently, we suggest that the findings of ATTRACT and CAVENT collectively argue against routine first-line thrombolysis for proximal DVT, but that patients with iliofemoral DVT or more severe presentations may derive benefit and deserve further examination.

This exploratory analysis of the iliofemoral DVT subgroup in the ATTRACT Trial did not find an effect of PCDT upon the development of “any PTS” over 2 years using the pre-specified primary trial outcome (Villalta score threshold of 5), and did not find an effect upon bleeding. These findings were similar in the per-protocol analysis, and they are consistent with PCDT treatment effects for “any PTS” in the iliofemoral and femoral-popliteal subgroups that did not differ significantly ( $p$ -interaction=0.85) (18). Although PCDT reduced the occurrence of PTS in a pre-specified secondary assessment using the VCSS, we chose the Villalta scale as the trial’s primary outcome measure based upon a more extensive body of literature and international societal recommendations supporting its use to detect incident PTS, including more rigorous assessment of the Villalta threshold

score than the VCSS threshold score (23-26). Additional studies to compare the performance characteristics of these two PTS scales, using the ATTRACT and other datasets, would be worthwhile.

The data from this analysis collectively suggest that PCDT improves short-term recovery from DVT and reduces long-term progression of PTS severity in patients with iliofemoral DVT. Evidence favoring PCDT includes: 1) greater reduction in leg pain and swelling through 30 days ( $p < 0.01$ ); 2) reduced PTS severity ( $p < 0.01$  for Villalta and VCSS comparisons) at 6, 12, 18, and 24 months; 3) reduced occurrence of moderate-or-severe PTS ( $p = 0.021$  for comparison of proportion with Villalta 10) and severe PTS ( $p < 0.05$  for comparisons of proportions with Villalta 15 and VCSS 8) through 24 months; and 4) greater improvement in venous disease-specific QOL from baseline to 24 months (5.6 points on VEINES-QOL scale,  $p = 0.029$ ). These findings were consistent in the per-protocol analyses.

However, the findings of this analysis should not be considered conclusive evidence that PCDT reduces the occurrence of moderate-or-severe PTS in patients with iliofemoral DVT. Moderate-or-severe PTS was one of a number of secondary outcomes. Although assessors were blinded to treatment arm, healthcare providers and patients were not blinded. Hence, further studies are recommended to determine whether PCDT truly reduces moderate-or-severe PTS in patients with iliofemoral DVT.

In this analysis, there was a suggestion that PCDT exerted a more positive effect upon the moderate-or-severe PTS outcome in iliofemoral DVT patients who were  $< 65$  years of age versus those  $\geq 65$  years old ( $p$ -interaction = 0.04), and upon patients whose DVT was provoked by a major reversible risk factor ( $p$ -interaction = 0.05). However, as these two results are in subgroups within the iliofemoral subgroup, and as they are among many outcomes that were evaluated in the study, and as the tests of interaction were not strongly positive, these two findings may have occurred by chance (39,40).

Our analysis has several limitations. First, there was substantial loss to follow-up that was unbalanced between the treatment groups (more missed PTS assessments in the No-PCDT Arm), which influenced the study's estimates of treatment effects (18). As only 57% of ATTRACT Trial patients had iliofemoral DVT, power to detect differences in outcomes with PCDT versus No-PCDT in the iliofemoral DVT subgroup is substantially less than in the overall trial. Furthermore, in the absence of a statistically significant test of interaction to support a difference in the PCDT treatment effect upon moderate-or-severe PTS between the iliofemoral and femoral-popliteal subgroups, the treatment effect estimate from the overall trial may be the most reliable estimate of the treatment effect in each of these two subgroups (39,40). This is also true for the assessment of bleeding, which was statistically higher with use of PCDT in the overall ATTRACT Trial. On the other hand, tests of interaction to detect differences in treatment effects between subgroups have low power in a medium-sized study such as ATTRACT. Strengths of this analysis include that it was pre-specified; that the presence of iliofemoral DVT was a stratification variable that was identified prior to randomization; and that the reduction in PTS severity with PCDT was a consistent finding across multiple venous outcome measures. We excluded patients with either asymptomatic

DVT or DVT causing acute circulatory compromise since they could not be ethically randomized to one or the other treatment strategy, and we acknowledge that a) the enrolled patients had varying baseline symptom severity (and perhaps PTS risk); b) patients with recurrent ipsilateral DVT within the last 2 years (who are expected to have a high risk of PTS) were excluded; and c) site investigators could have chosen to bypass the study for selected patients at either end of the severity spectrum. However, throughout the study we provided detailed education to study centers that explicitly addressed this issue and strongly encouraged the enrollment of all willing iliofemoral DVT patients who met the study eligibility criteria. This analysis is also the largest report of randomized trial outcomes specifically in patients with iliofemoral DVT.

In conclusion, the findings of this exploratory analysis strongly suggest that PCDT reduces acute leg pain and swelling, reduces PTS severity, and improves venous QOL in patients with acute iliofemoral DVT. These findings support early use of PCDT in patients with acute iliofemoral DVT who have severe symptoms, low bleeding risk, and who attach greater importance to a reduction in early and late symptoms than to the risks, cost, and inconvenience of PCDT. A decision to use PCDT should factor in this study's limitations (including the lack of patient blinding) and should be made only after a careful review of the bleeding risk in that individual patient. Further prospective study of PCDT and other endovascular therapies should be targeted to the subset of patients with iliofemoral DVT.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGEMENTS

The study's development and conduct were supported by the Society of Interventional Radiology Foundation. Dr. Kahn is a Tier 1 Canada Research Chair holder and is an investigator of the Canadian Institutes of Health Research-funded CanVECTOR Network. Dr. Kearon is supported by an Investigator Award from the Heart and Stroke Foundation of Canada and the Jack Hirsh Professorship in Thromboembolism. The authors wish to thank the entire network of investigators and study staff at the coordinating centers, core laboratories, and clinical centers (see Supplement).

### SOURCES OF FUNDING

The ATTRACT Trial was supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for the clinical coordinating center (U01-088476 to Dr. Suresh Vedantham, Washington University in St. Louis) and data coordinating center (U01-088118 for Dr. Clive Kearon, McMaster University in Hamilton, Ontario); Washington University's Center for Translational Therapies in Thrombosis which is supported by a grant from NHLBI (U54-HL112303), the Washington University Institute of Clinical & Translational Sciences which is supported by a grant from National Center for the Advancement of Translational Sciences (NCATS) of NIH (UL1-TR00044810); the Canada Research Chairs Program (Tier 1 support to Dr. Kahn); the Heart and Stroke Foundation of Canada (Investigator Award to Dr. Kearon); and a Jack Hirsh Professorship in Thrombosis (to Dr. Kearon). Boston Scientific and Covidien (now Medtronic) provided supplemental funding. Study drug and funding were provided by Genentech. Compression stockings were donated by BSN Medical. These companies played no role in the study's design, conduct, analysis, or reporting.

## Appendix - ATTRACT Investigators

Radica Alicic, MD

Providence Sacred Heart Medical Center & Children's Hospital

Spokane, WA  
John Angle, MD  
University of Virginia Health System  
Charlottesville, VA  
Ezana Azene, MD, PhD  
Gundersen Clinic  
LaCrosse, WI  
Riyaz Bashir, MD  
Temple University Hospital  
Philadelphia, PA  
Sumit Bhatla, MD  
Riverside Methodist Hospital  
Columbus, OH  
Haraldur Bjarnason, MD  
Mayo Clinic  
Rochester, MN  
Carl Black, MD  
Utah Valley Regional Medical Center  
Salt Lake City, UT  
Morey Blinder, MD  
Washington University in St. Louis  
St. Louis, MO  
Paul Brady, MD  
Albert Einstein Medical Center  
Philadelphia, PA  
Rabih Chaer, MD

University of Pittsburgh  
Pittsburgh, PA  
Thomas Chang, MD  
Georgetown University  
Washington, D.C.  
David J. Cohen, MD, MSc  
St. Luke's Mid America Heart Institute  
Kansas City, MO  
Anthony Comerota, MD  
Jobst Vascular Center  
Toledo, OH  
Alan Dietzek, MD  
Danbury Hospital  
Danbury, CT  
Mark Garcia, MD  
Christiana Care Hospital  
Newark, DE  
Randolph Geary, MD  
Wake Forest Baptist Health  
Winston-Salem, NC  
Swapna Goday, MD  
Western Penn Allegheny Health System  
Pittsburgh, PA  
Samuel Z. Goldhaber, MD  
Brigham and Women's Hospital  
Boston, MA

Heather L. Gornik, MD, MHS  
Cleveland Clinic Heart & Vascular Institute  
Cleveland, OH  
Chu-Shu Gu, PhD  
McMaster University  
Hamilton, ON (Canada)  
Marcelo Guimaraes, MD  
Medical University of South Carolina  
Charleston, SC  
Ziv Haskal, MD  
University of Maryland  
Baltimore, MD  
Kevin Herman, MD  
Holy Name Hospital  
Teaneck, NJ  
Kim Hodgson, MD  
Southern Illinois University  
Springfield, IL  
Lawrence Hofmann, MD  
Stanford University Medical Center  
Stanford, CA  
David Hunter, MD  
University of Minnesota  
Minneapolis, MN  
Darren Hurst, MD  
St. Elizabeth Healthcare



Edgewood, KY  
Michael R. Jaff, DO  
Massachusetts General Hospital  
Boston, MA  
Jim Julian, MMath  
McMaster University  
Hamilton, ON (Canada)  
Susan R. Kahn, MD, MSc  
Jewish General Hospital  
Montreal, QC (Canada)  
John Kaufman, MD  
Oregon Health & Science University  
Portland, OR  
Clive Kearon, MB, PhD  
McMaster University  
Hamilton, ON (Canada)  
Stephen Kee, MD  
Society of Interventional Radiology Foundation  
Fairfax, VA  
Paul Kim, MD  
Maine Medical Center  
Portland, ME  
Stanley Kim, MD  
Central DuPage Hospital  
Winfield, IL  
Andrei Kindzelski, MD, PhD

National Heart Lung and Blood Institute

Bethesda, MD

Seth Klein, MD

Washington University in St. Louis

St. Louis, MO

Venkataramu Krishnamurthy, MD

Ann Arbor VA Health Center

Ann Arbor, MI

Daniel Leung, MD

Christiana Care Hospital

Newark, DE

Lawrence Lewis, MD

Washington University in St. Louis

St. Louis, MO

Judith Lin, MD

Henry Ford Health System

Detroit, MI

Elizabeth Magnuson, ScD

St. Luke's Mid America Heart Institute

Kansas City, MO

Rahul Malhotra, MD

Phoenix Heart & Cardiovascular Institute

Glendale, AZ

John Marek, MD

University of New Mexico

Albuquerque, NM

Vasco Marques, MD  
Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute  
Tampa, FL

Robert McLafferty, MD  
Southern Illinois University  
Springfield, IL

Sanjay Misra, MD  
Mayo Clinic  
Rochester, MN

Stephan Moll, MD  
University of North Carolina  
Chapel Hill, NC

Stephen Motew, MD  
Forsyth Medical Center  
Winston-Salem, NC

Patrick Muck, MD  
Good Samaritan Hospital  
Cincinnati, OH

Timothy P. Murphy, MD  
Rhode Island Hospital  
Providence, RI

Kannan Natarajan, MD  
St. Vincent Medical Group  
Indianapolis, IN

Neil Patel, MD  
Central DuPage Hospital

Winfield, IL  
Parag Patel, MD  
Medical College of Wisconsin  
Milwaukee, WI  
Rajul Patel, MD  
Phoenix Heart & Cardiovascular  
Phoenix, AZ  
Rodney Raabe, MD  
Providence Sacred Heart Medical Center & Children's Hospital  
Spokane, WA  
Mark Ranson, MD  
Florida Hospital  
Orlando, FL  
Mahmood Razavi, MD  
St. Joseph Hospital  
Orange, CA  
Rahul Razdan, MD  
St. Elizabeth Regional Medical Center  
Lincoln, NE  
Charles Ray, MD, PhD  
University of Illinois Medical Center  
Chicago, IL  
John Rundback, MD  
Holy Name Medical Center  
Teaneck, NJ  
Nael Saad, MD

Washington University in St. Louis

St. Louis, MO

Wael Saad, MD

University of Michigan

Ann Arbor, MI

David Sacks, MD

The Reading Hospital

West Reading, PA

Shaun Samuels, MD

Baptist Cardiac and Vascular Institute

Miami, FL

Robert Schainfeld, MD

Massachusetts General Hospital

Boston, MA

Joseph Schneider, MD, PhD

Central DuPage Hospital

Winfield, IL

Jonathan Schor, MD

Staten Island University Hospital

Staten Island, NY

Melhem Sharafuddin, MD

University of Iowa

Iowa City, IA

Karun Sharma, MD, PhD

Georgetown University

Washington, D.C.

Michael Sichlau, MD  
Adventist Midwest Health  
La Grange, IL  
Akhilesh Sista, MD  
Weill Cornell Medical College  
New York, NY  
Dennis Slater, MD  
Eastern Connecticut Hematology & Oncology Associates  
Norwich, CT  
Gregory Soares, MD  
Rhode Island Hospital  
Providence, RI  
Jamie Thomas, MD  
St. Luke's Hospital and Health Network  
Bethlehem, PA  
Eric VanderWoude, MD  
St. Elizabeth Regional Medical Center  
Lincoln, NE  
Suresh Vedantham, MD  
Washington University in St. Louis  
St. Louis, MO  
Adarsh Verma, MD  
Mease Countryside Hospital  
Clearwater, FL  
Russel Vinik, MD  
University of Utah Medical Center



Salt Lake City, UT  
Brandt Wible, MD  
St. Luke's Hospital  
Kansas City, MO  
Stephan Wicky, MD  
Massachusetts General Hospital  
Boston, MA  
David Williams, MD  
University of Michigan Hospitals and Health Centers  
Ann Arbor, MI  
Ronald Winokur, MD  
Weill Cornell College of Medicine  
New York, NY

## REFERENCES

1. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation*. 2011; 123:1788–1830. [PubMed: 21422387]
2. Vedantham S, Grassi CJ, Ferral H, Patel NH, Thorpe PE, Antonacci VP, Janne D'Othee BM, Hofmann LV, Cardella JF, Kundu S, Lewis CA, Schwartzberg MS, Min RJ, Sacks D; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. *J Vasc Interv Radiol* 2006; 17:417–434. [PubMed: 16567667]
3. O'Donnell TF, Browse NL, Burnand KG, Thomas ML. The socio-economic effects of an iliofemoral venous thrombosis. *J Surg Res* 1977; 22:483–488. [PubMed: 140274]
4. Comerota AJ, Gravett MH. Iliofemoral venous thrombosis. *J Vasc Surg* 2007; 46(5):1065–76. [PubMed: 17980295]
5. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effect on venous hemodynamics, clinical status, quality of life. *Ann Surg* 2004; 239:118–126. [PubMed: 14685109]
6. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? *Am J Med* 2001; 110:515–519. [PubMed: 11343664]
7. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Ann Intern Med* 2008; 149:698–707. [PubMed: 19017588]

8. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. *Radiology*. 1999; 211:39–49. [PubMed: 10189452]
9. Comerota AJ, Thom RC, Mathias SD, Haughton S, Mewissen M. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. *J Vasc Surg* 2000; 32:130–137. [PubMed: 10876214]
10. Aziz F, Comerota AJ. Quantity of residual thrombus after successful catheter-directed thrombolysis for iliofemoral deep vein thrombosis correlates with recurrence. *Eur J Vasc Endovasc Surg* 2012; 44:210–213. [PubMed: 22658610]
11. Enden T, Haig Y, Klow N, Slagsvold CE, Sandvik L, Ghanima W, Hafsaal G, Holme PA, Holmen LO, Njaastad AM, Sandb00E6k G, Sandset PM; CaVenT Study Group. Long-term outcomes after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. *Lancet* 2012; 379:31–38. [PubMed: 22172244]
12. Comerota AJ, Grewal N, Martinez JT, Chen JT, DiSalle R, Andrews L, Sepanski D, Assi Z. Post-thrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. *J Vasc Surg* 2012; 55: 768–773. [PubMed: 22277690]
13. Haig Y, Enden T, Slagsvold C, Sandvik L, Sandset PM, Klow NE. Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep venous thrombosis. *J Vasc Interv Radiol* 2013; 24:17–24. [PubMed: 23176966]
14. Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness DE. Deep venous insufficiency: the relationship between lysis and subsequent reflux. *J Vasc Surg* 1993; 18:596–608. [PubMed: 8411467]
15. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. *Am J Med* 1984; 76:393–397. [PubMed: 6367454]
16. Labropoulos N, Volteas N, Leon L, Sowade O, Rulo A, Giannoukas AD. The role of venous outflow obstruction in patients with chronic venous dysfunction. *Arch Surg* 1997; 132:46–51. [PubMed: 9006552]
17. Vedantham S, Goldhaber SZ, Kahn SR, Julian J, Magnuson E, Jaff MR, Murphy TP, Cohen DJ, Comerota AJ, Gornik HL, Razavi MK, Lewis L, Kearon C. Rationale and design of the ATTRACT Study: A multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. *Am Heart J*. 2013; 165:523–553. [PubMed: 23537968]
18. Vedantham S, Goldhaber SZ, Julian J, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu C, Kee S, Schneider JR, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. *N Engl J Med* 2017; 377:2240–2252. [PubMed: 29211671]
19. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines *Chest*. 2012; 141:e419S–494S. [PubMed: 22315268]
20. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris T, Sood N, Stevens SM, Vintch JRE, Wells PE, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest*. 2016; 149:315–352. [PubMed: 26867832]
21. Vedantham S, Thorpe PE, Cardella JF, Grassi CJ, Patel NH, Ferral H, Hofmann LV, Janne d’Othee BM, Antonacci VP, Brountzos EN, Brown DB, Martin LG, Matsumoto AH, Meranze SG, Miller DL, Millward SF, Min RJ, Neithamer CD, Rajan DK, Rholl KS, Schwartzberg MS, Swan TL, Towbin RB, Wiechmann BN, Sacks D; CIRSE and SIR Standards of Practice Committees. Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal. *J Vasc Interv Radiol* 2006; 17:435–448. [PubMed: 16567668]

22. Vedantham S, Sista AK, Klein SJ, Nayak L, Razavi MK, Kalva SP, Saad WE, Dariushnia S, Caplin DM, Chao C, Ganguli S, Walker TG, Nikolic B; for the Society of Interventional Radiology and Cardiovascular and Interventional Radiological Society of Europe Standards of Practice Committees; Society of Interventional Radiology and Cardiovascular and Interventional Radiological Society of Europe Standards of Practice Committees. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. *J Vasc Interv Radiol* 2014; 25:1317–1325. [PubMed: 25000825]
23. Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. *J Thromb Haemost* 2009; 7:884–888. [PubMed: 19320818]
24. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. *J Thromb Haemost* 2009; 7:879–883. [PubMed: 19175497]
25. Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, Meissner MH, Rutherford RB; American Venous Forum Ad Hoc Outcomes Working Group. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. *J Vasc Surg* 2010; 52:1387–1396. [PubMed: 20875713]
26. Meissner MH, Natiello C, Nicholls SC. Performance characteristics of the venous clinical severity score. *J Vasc Surg* 2002; 36:889–895. [PubMed: 12422097]
27. Ware JE, Kosinski M, Keller S. SF-36 physical and mental summary measures: A user's manual. Boston: The Health Institute, New England Medical Center 1994.
28. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. *J Vasc Surg* 2003; 37:410–419. [PubMed: 12563215]
29. Bernstein SL, Chang A, Esses D, Gallagher EJ. Relationship between intensity and relief in patients with acute, severe pain. *Acad Emerg Med* 2005; 12:158–159. [PubMed: 15692138]
30. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. *J Lab Clin Med* 1977; 89:1018–1029. [PubMed: 323387]
31. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005; 3:692–694. [PubMed: 15842354]
32. Cleveland WS, Devlin SJ. Locally-weighted regression: an approach to regression analysis by local fitting. *J Am Stat Assoc*. 1988; 83:596–610.
33. Engelberger RP, Spirk D, Willenberg T, Alatri A, Do D, Baumgartner I, Kucher N. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis. *Circ Cardiovasc Interv* 2015; 8:e002027 (PMID: 25593121). [PubMed: 25593121]
34. Engelberger RP, Stuck A, Spirk D, Willenberg T, Haine A, Periard D, Baumgartner I, Kucher N. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: 1-year follow-up data of a randomized controlled trial. *J Thromb Haemost* 2017; 15:1351–1360. [PubMed: 28440041]
35. Vedantham S, Kahn SR, Goldhaber SZ, Comerota AJ, Parpia S, Meleth S, Earp D, Williams R, Sista AK, Marston W, Rathbun S, Magnuson EA, Razavi MK, Jaff MR, Kearon C. Endovascular therapy for advanced post-thrombotic syndrome: proceedings from a multidisciplinary consensus panel. *Vasc Med* 2016; 21:400–407. [PubMed: 27247235]
36. Plate G, Akesson H, Einarsson E, Ohlin P, Eklor B. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. *Eur J Vasc Surg* 1990; 4:483–489. [PubMed: 2226879]
37. AbuRahma AF, Perkins SE, Wulu JT, Ng HK. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. *Ann Surg* 2001; 233(6):752–760. [PubMed: 11371733]
38. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. *Eur J Vasc Endovasc Surg* 2002; 24: 209–214. [PubMed: 12217281]

39. Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JP. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. *JAMA Intern Med* 2017; 177:554–560. [PubMed: 28192563]
40. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, Bassler D, Mertz D, Diaz-Granados N, Vandvik PO, Malaga G, Srinathan SK, Dahm P, Johnston BC, Alonso-Coello P, Hassouneh B, Walter SD, Heels-Ansdell D, Bhatnagar N, Altman DG, Guyatt GH. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. *Br Med J*. 2012; 344:e1553. [PubMed: 22422832]


## CLINICAL PERSPECTIVE

### What is new?

- Outcomes are reported on a subgroup of 391 patients with acute iliofemoral DVT in whom pharmacomechanical catheter-directed thrombolysis (PCDT) was evaluated within a large multicenter randomized controlled trial (ATTRACT).
- In patients with acute iliofemoral DVT, PCDT does not influence the occurrence of the post-thrombotic syndrome (PTS) or recurrent venous thromboembolism through 24 months.
- In patients with acute iliofemoral DVT, PCDT does appear to provide greater reduction in acute leg pain and swelling through 30 days follow-up, as well as reduced PTS severity, reduced moderate-or-severe PTS, and greater improvement in venous disease-specific quality of life through 24 months.


### What are the clinical implications?

- The findings support early use of PCDT in patients with acute iliofemoral DVT who have severe symptoms, low bleeding risk, and who attach greater importance to a reduction in early and late symptoms than to the risks, costs, and inconvenience of PCDT.



**Figure 1. Patient flow diagram for the iliofemoral DVT subgroup in the ATTRACT trial.**  
PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep-vein thrombosis;  
LEP, Late Endovascular Procedure (not including inferior vena cava filter).







**Figure 2. Subgroup analysis of PTS in patients with iliofemoral DVT.**

Forest plot of risk ratios (PCDT versus No PCDT) for the occurrence of PTS from 6 to 24 months among subgroups of patients. The horizontal lines represent 99% confidence intervals.

PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis.



**Figure 3: LOESS\* of raw and predicted mean Villalta scores by treatment group**  
 Graphical display (locally weighted scatterplot smoothing) of the Villalta Scores evaluating PTS severity by treatment arm, derived from piecewise-linear growth-curve models of the repeated assessments from baseline through 24 months.



**Figure 4. Subgroup analysis of moderate-or-severe PTS in patients with iliofemoral DVT.**

Forest plot of risk ratios (PCDT versus No PCDT) for the occurrence of moderate-or-severe PTS from 6 to 24 months among subgroups of patients. The horizontal lines represent 99% confidence intervals.

PCDT, pharmacomechanical catheter-directed thrombolysis; DVT, deep vein thrombosis.

**Table 1:**

## Baseline Characteristics by Treatment Group

| Baseline Characteristic  | PCDT<br>n = 196 | No PCDT<br>n = 195 | Total<br>N = 391 |
|--|-----------------|--------------------|------------------|
| Age, years: <i>median (IQR)</i>  | 51 (39, 62)     | 52 (42, 61)        | 52 (39, 62)      |
| Male: <i>n (%)</i>   | 107 (55)        | 101 (52)           | 208 (53)         |
| <b>Race: <i>n (%)</i></b>  |                 |                    |                  |
| White  | 158 (81)        | 148 (76)           | 306 (78)         |
| Black/African-American   | 33 (17)         | 35 (18)            | 68 (17)          |
| Other  | 5 (3)           | 12 (6)             | 17 (4)           |
| Body mass index, kg/m <sup>2</sup> : <i>median (IQR)</i>                         | 31 (28, 37)     | 31 (26, 36)        | 31 (27, 37)      |
| <b>Symptom severity (Villalta<sup>*</sup>) class: <i>n (%)</i><sup>†</sup></b>   |                 |                    |                  |
| None or minimal (score 0-4)  | 24 (12)         | 31 (16)            | 55 (14)          |
| Mild (score 5-9)   | 65 (33)         | 65 (33)            | 130 (33)         |
| Moderate (score 10-14)   | 60 (31)         | 56 (29)            | 116 (30)         |
| Severe (score 15)  | 47 (24)         | 42 (22)            | 89 (23)          |
| Leg with index DVT, Left: <i>n (%)</i>   | 124 (63)        | 125 (64)           | 249 (64)         |
| Previous DVT or PE: <i>n (%)</i>   | 48 (24)         | 45 (23)            | 93 (24)          |
| Previous ipsilateral DVT: <i>n (%)</i>   | 3 (2)           | 10 (5)             | 13 (3)           |
| <b>DVT risk factors: <i>n (%)</i><sup>‡</sup></b>                                |                 |                    |                  |
| Major surgery  | 19 (10)         | 21 (11)            | 40 (10)          |
| Hospitalization  | 17 (9)          | 29 (15)            | 46 (12)          |
| Plaster cast immobilization  | 7 (4)           | 3 (2)              | 10 (3)           |
| Childbirth   | 3 (2)           | 5 (3)              | 8 (2)            |
| Outpatient: <i>n (%)</i>   | 156 (80)        | 156 (80)           | 312 (80)         |
| Days from start of DVT symptoms to rand: <i>median (IQR)</i>                     | 6 (3, 9)        | 6 (3, 9)           | 6 (3, 9)         |
| eGFR, mL/min: <i>median (IQR)</i>  | 84 (67, 103)    | 88 (72, 104)       | 86 (70, 103)     |
| <b>Leg pain severity: <i>n (%)</i></b>   |                 |                    |                  |
| 0-2  | 34 (17)         | 43 (22)            | 77 (20)          |
| 3-4  | 60 (31)         | 59 (30)            | 119 (30)         |
| 5-7  | 99 (51)         | 91 (47)            | 190 (49)         |
| Unknown  | 3 (2)           | 2 (1)              | 5 (1)            |
| <b>Between-leg circumference difference<sup>§</sup>, cm: <i>median (IQR)</i></b> | 3 (2, 5)        | 3 (2, 4)           | 3 (2, 5)         |
| <b>Pre-randomization AC<sup>  </sup> therapy: <i>n (%)</i><sup>‡</sup></b>       | 180 (92)        | 184 (94)           | 364 (93)         |

| Baseline Characteristic | PCDT<br>n = 196 | No PCDT<br>n = 195 | Total<br>N = 391 |
|-------------------------|-----------------|--------------------|------------------|
| LMWH                    | 101 (56)        | 110 (60)           | 211 (58)         |
| UFH                     | 61 (34)         | 60 (33)            | 121 (33)         |
| Rivaroxaban             | 7 (4)           | 7 (4)              | 14 (4)           |
| Warfarin                | 89 (49)         | 98 (53)            | 187 (51)         |
| Other                   | 11 (6)          | 7 (4)              | 18 (5)           |

\* **Villalta Scale:** 5 patient-reported signs (cramps, itching, pins & needles, leg heaviness, pain) and 6 blinded clinician-reported symptoms (pretibial edema, skin induration, hyperpigmentation, venous ectasia, redness, pain during calf compression) scored on a 4-point scale (0=none/minimal, 1=mild, 2=moderate, 3=severe) and summed into a total score, or the presence of an ulcer (score=15), for the leg with index DVT

<sup>†</sup> One patient in the No PCDT was not assessed

<sup>‡</sup> Subjects may fit into more than one category

<sup>§</sup> Leg circumference with index DVT minus Leg circumference of the other leg

// Anticoagulant (AC) therapy that was given after DVT diagnosis and before randomization

IQR, inter-quartile range; DVT, deep vein thrombosis; PE, pulmonary embolism; rand, randomization; eGFR, estimated glomerular filtration rate; LMWH, low molecular weight heparin; UFH, unfractionated heparin

**Table 2:**

## Study Treatments Post Randomization

| Treatment over Time                                       | PCDT<br>n = 196 | No PCDT<br>n = 195 |
|---|-----------------|--------------------|
| <b>Initial AC* therapy: n (%)<sup>†</sup></b>             | <i>n</i> = 194  | <i>n</i> = 193     |
| UFH   | 73 (38)         | 42 (22)            |
| LMWH  | 99 (51)         | 132 (68)           |
| Other   | 29 (15)         | 28 (15)            |
| <b>At 30 days: n (%)<sup>†</sup></b>                      | <i>n</i> = 183  | <i>n</i> = 173     |
| Any AC Therapy  | 177 (97)        | 167 (97)           |
| Antiplatelet Therapy                                      | 30 (16)         | 26 (15)            |
| Compression stockings used 3 days per week                | 135 (74)        | 136 (79)           |
| <b>At 6 months: n (%)<sup>†</sup></b>                     | <i>n</i> = 169  | <i>n</i> = 150     |
| Any AC Therapy  | 136 (80)        | 126 (84)           |
| Antiplatelet Therapy                                      | 34 (20)         | 23 (15)            |
| Compression stockings used 3 days per week                | 111 (66)        | 108 (72)           |
| <b>At 24 months: n (%)<sup>†</sup></b>                    | <i>n</i> = 141  | <i>n</i> = 131     |
| Any AC Therapy  | 66 (47)         | 68 (52)            |
| Antiplatelet Therapy                                      | 44 (31)         | 39 (30)            |
| Compression stockings used 3 days per week                | 77 (55)         | 74 (56)            |
| <b>Duration of AC therapy: n (%)</b>                      |                 |                    |
| Never started   | 2 (1)           | 2 (1)              |
| Not stopped during study period                           | 106 (54)        | 108 (55)           |
| Stopped during study period:                              | 88 (45)         | 85 (44)            |
| Days to stopping: <i>median (IQR)</i>                     | 213 (182, 367)  | 270 (182, 395)     |
| <b>PCDT Procedure Details (PCDT Arm only)</b>             |                 |                    |
| <b>Initial rt-PA delivery method:</b>                     |                 |                    |
| <b>Infusion-First: n (%)</b>                              | 102 (52)        |                    |
| rt-PA total dose, mg: <i>median (IQR)</i>                 | 21 (18, 26)     |                    |
| rt-PA duration, hours: % below 4h, mean (SD) <sup>‡</sup> | 0%, 23 (7.2)    |                    |
| <b>AngioJet: n (%)</b>                                    | 46 (24)         |                    |
| rt-PA total dose, mg: <i>median (IQR)</i>                 | 21 (15, 28)     |                    |
| rt-PA duration, hours: % below 4h, mean (SD) <sup>‡</sup> | 46%, 20 (5.5)   |                    |
| <b>Trellis: n (%)</b>                                     | 38 (19)         |                    |
| rt-PA total dose, mg: <i>median (IQR)</i>                 | 20 (12, 30)     |                    |
| rt-PA duration, hours: % below 4h, mean (SD) <sup>‡</sup> | 58%, 20 (4.6)   |                    |

| <b>PCDT Procedure Details (PCDT Arm only)</b>       |            |
|---|------------|
| <b>Initial rt-PA delivery method:</b>               |            |
| <b>Other<sup>§</sup>: n (%)</b>                     | 10 (5)     |
| <b>Additional endovascular methods used: n (%)</b>  |            |
| None  | 18 (9)     |
| 1 or more   | 178 (91)   |
| <b>Type of additional method: n (%)<sup>‡</sup></b> |            |
| Balloon venoplasty                                  | 128 (72)   |
| Balloon maceration                                  | 105 (59)   |
| Rheolytic thrombectomy (AngioJet)                   | 104 (58)   |
| Stent placement                                     | 70 (39)    |
| Large-bore catheter aspiration                      | 44 (25)    |
| Isolated thrombolysis (Trellis)                     | 11 (6)     |
| <b>Veins that were accessed: n (%)<sup>‡</sup></b>  |            |
| Ipsilateral Popliteal Vein                          | 172 (90)   |
| Ipsilateral Tibial Vein                             | 12 (6)     |
| Ipsilateral Common Femoral Vein                     | 5 (3)      |
| Internal Jugular Vein                               | 12 (6)     |
| Other Vein  | 17 (9)     |
| <b>Marder scores: median (IQR)</b>                  |            |
| Pre-lysis (n=180)                                   | 11 (8, 16) |
| Post-lysis (n=178)                                  | 2 (0, 4)   |
| Pre-post Decrease (n=176)                           | 9 (4, 13)  |

\* Anticoagulation (AC) therapy given post randomization

<sup>‡</sup> Subjects may fit into more than one category

<sup>‡</sup> Distributions are bimodal with spikes below 4 hours (means and SDs are for post 4-hour data)

<sup>§</sup> 6 PCDT procedures where there was no acute thrombus on venogram and 4 not attempted

IQR, Inter-quartile range; rt-PA, recombinant tissue plasminogen activator; SD, standard deviation

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3:**

Binary Study Outcomes by Treatment Group (Intention-to-Treat Analysis)

| Outcome  | PCDT<br>n = 196 |        | No PCDT<br>n = 195 |        | Risk Ratio        |            | P<br>Value |
|--|-----------------|--------|--------------------|--------|-------------------|------------|------------|
|  | Events          | (%)    | Events             | (%)    | Estimate          | 95% CI     |            |
| <b>PTS<sup>*</sup>:</b>                                      |                 |        |                    |        |                   |            |            |
| Ulcer (any assessment)                                       | 9               | (4.6%) | 12                 | (6.2%) |                   |            |            |
| Villalta 5 (without ulcer)                                   | 86              | (44%)  | 88                 | (45%)  |                   |            |            |
| Late endovascular procedure only                             | 1               | (0.5%) | 0                  | (0%)   |                   |            |            |
| <b>Total</b>   | 96              | (49%)  | 100                | (51%)  | 0.95 <sup>*</sup> | 0.78, 1.15 | 0.59       |
| <b>PTS: VCSS 4<sup>*</sup></b>                               | 59              | (30%)  | 78                 | (40%)  | 0.75 <sup>*</sup> | 0.57, 0.98 | 0.034      |
| <b>PTS incidence proportion:<sup>†</sup></b>                 |                 |        |                    |        |                   |            |            |
| At 6 months  | 50/169          | (30%)  | 68/149             | (46%)  | 0.65              | 0.48, 0.87 |            |
| At 12 months   | 58/155          | (37%)  | 49/137             | (36%)  | 1.05              | 0.77, 1.42 |            |
| At 18 months   | 46/139          | (33%)  | 47/123             | (38%)  | 0.87              | 0.63, 1.20 |            |
| At 24 months   | 48/145          | (33%)  | 52/133             | (39%)  | 0.85              | 0.62, 1.16 |            |
| <b>Moderate-severe PTS (Villalta 10)<sup>‡</sup></b>         | 36              | (18%)  | 55                 | (28%)  | 0.65 <sup>*</sup> | 0.45, 0.94 | 0.021      |
| <b>Moderate-severe PTS incidence proportion:<sup>§</sup></b> |                 |        |                    |        |                   |            |            |
| At 6 months  | 19/169          | (11%)  | 29/149             | (19%)  | 0.58              | 0.34, 0.99 |            |
| At 12 months   | 18/155          | (12%)  | 24/137             | (18%)  | 0.66              | 0.38, 1.17 |            |
| At 18 months   | 16/139          | (12%)  | 23/123             | (19%)  | 0.62              | 0.34, 1.11 |            |
| At 24 months   | 17/145          | (12%)  | 25/133             | (19%)  | 0.62              | 0.35, 1.10 |            |
| <b>Severe PTS: Villalta 15<sup>  </sup></b>                  | 17              | (8.7%) | 30                 | (15%)  | 0.57 <sup>*</sup> | 0.32, 1.01 | 0.048      |
| <b>Severe PTS: VCSS 8<sup>  </sup></b>                       | 13              | (6.6%) | 28                 | (14%)  | 0.46 <sup>*</sup> | 0.24, 0.87 | 0.013      |
| <b>Major non-PTS treatment failure</b>                       | 4               | (2.0%) | 5                  | (2.6%) | 0.80              | 0.22, 2.92 | 0.73       |
| <b>Any treatment failure<sup>**</sup></b>                    | 97              | (49%)  | 103                | (53%)  | 0.93 <sup>*</sup> | 0.77, 1.13 | 0.47       |
| <b>Major bleeding in first 10 days</b>                       | 3               | (1.5%) | 1                  | (0.5%) | 2.98              | 0.31, 28.4 | 0.32       |
| <b>Any bleeding in first 10 days</b>                         | 7               | (3.6%) | 4                  | (2.1%) | 1.74              | 0.52, 5.85 | 0.36       |
| <b>VTE:</b>  |                 |        |                    |        |                   |            |            |
| First 30 days  | 11              | (5.8%) | 6                  | (3.1%) | 1.82              | 0.69, 4.83 | 0.22       |
| Total over 24 months   | 26              | (13%)  | 18                 | (9.2%) | 1.44              | 0.81, 2.53 | 0.21       |
| <b>Death</b>   | 6               | (3.1%) | 6                  | (3.1%) | 0.99              | 0.33, 3.03 | 0.99       |

\* Cochran-Mantel-Haenszel (CMH) test adjusted for center, cumulative proportion of patients who developed PTS at any time between 6-24 months, inclusive. Villalta scores (0-33 range); VCSS scores (0-27 range), higher is worse for both.



<sup>†</sup> At each visit, the proportion of patients with any PTS according to the Villalta scale among those who had an assessment performed (denominator)

<sup>‡</sup> Cumulative proportion with moderate or severe PTS (pre-specified analysis)

<sup>§</sup> At each visit, the proportion of patients with moderate or severe PTS according to the Villalta scale among those who had an assessment performed (denominator)

<sup>||</sup> Cumulative proportion with severe PTS

<sup>\*\*</sup> Composite of PTS or major non-PTS treatment failure.

PTS, post-thrombotic syndrome; CI, confidence interval; VTE, venous thromboembolism

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 4:**

## Continuous Study Outcomes by Treatment Group (Intention-to-Treat Analysis)

| Outcome   | PCDT<br>n = 196 |              | No PCDT<br>n = 195 |              | PCDT – No PCDT<br>Difference |         |
|---|-----------------|--------------|--------------------|--------------|------------------------------|---------|
|   | n               | mean (SE)    | n                  | mean (SE)    | Estimate (SE)                | P-value |
| <b>Villalta mean scores<sup>*†</sup>:</b>                       |                 |              |                    |              |                              |         |
| At 6 months   | 169             | 3.70 (0.51)  | 149                | 5.38 (0.50)  | -1.68 (0.47)                 | <0.001  |
| At 12 months  | 155             | 3.78 (0.50)  | 137                | 5.43 (0.49)  | -1.65 (0.45)                 | <0.001  |
| At 18 months  | 139             | 3.86 (0.52)  | 123                | 5.49 (0.50)  | -1.62 (0.48)                 | <0.001  |
| At 24 months  | 145             | 3.95 (0.54)  | 133                | 5.54 (0.54)  | -1.60 (0.54)                 | 0.0033  |
| <b>VCSS mean scores<sup>‡§</sup>:</b>                           |                 |              |                    |              |                              |         |
| At 6 months   | 168             | 1.82 (0.32)  | 145                | 2.98 (0.32)  | -1.16 (0.28)                 | <0.001  |
| At 12 months  | 151             | //           | 134                | //           | //                           | //      |
| At 18 months  | 135             | 1.67 (0.35)  | 121                | 3.43 (0.35)  | -1.76 (0.34)                 | <0.001  |
| At 24 months  | 132             | 1.98 (0.35)  | 122                | 2.80 (0.35)  | -0.82 (0.34)                 | 0.018   |
| <b>SF-36 general Quality of Life<sup>†‡</sup>: **</b>           |                 |              |                    |              |                              |         |
| PCS: Change, baseline to 24 months                              | 141             | 10.65 (0.95) | 128                | 11.43 (0.99) | -0.78 (1.17)                 | 0.51    |
| MCS: Change, baseline to 24 months                              | 141             | 2.85 (0.82)  | 128                | 4.02 (0.86)  | -1.17 (1.09)                 | 0.28    |
| <b>VEINES disease-specific Quality of Life<sup>†‡</sup>: ††</b> |                 |              |                    |              |                              |         |
| Overall: Change, baseline to 24 months                          | 141             | 28.63 (1.97) | 128                | 23.02 (2.07) | 5.61 (2.6)                   | 0.029   |
| Symptoms: Change, baseline to 24 months                         | 140             | 21.45 (1.96) | 128                | 16.24 (2.06) | 5.21 (2.56)                  | 0.043   |
| <b>Leg pain severity<sup>††</sup> (7-point scale): §§</b>       |                 |              |                    |              |                              |         |
| Change, baseline to Day 10                                      | 181             | -1.76 (0.14) | 177                | -1.25 (0.14) | -0.51 (0.19)                 | 0.0093  |
| Change, baseline to Day 30                                      | 178             | -2.36 (0.15) | 171                | -1.80 (0.15) | -0.56 (0.21)                 | 0.0082  |
| <b>Index leg circumference<sup>††</sup> (cm): §§§</b>           |                 |              |                    |              |                              |         |
| Change, baseline to Day 10                                      | 175             | -0.79 (0.23) | 177                | 0.22 (0.23)  | -1.00 (0.32)                 | 0.0019  |
| Change, baseline to Day 30                                      | 174             | -1.37 (0.22) | 170                | -0.10 (0.23) | -1.27 (0.32)                 | <0.001  |

\* Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and piece-wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race)

<sup>†</sup>Villalta scores (0-33 range) – higher is worse

<sup>‡</sup>Mean scores, standard errors (SE) and treatment differences estimated using growth curve models and piece-wise linear regression adjusted for center, and baseline covariates (age, sex, BMI, race, Villalta score)

<sup>§</sup>VCSS scores (0-27 range) – higher is worse

// Model estimates are unchanged from month 6 to month 12 due to the lack of a significant time trend

\*\* SF-36 major scales: physical component score (PCS, 0-100 range) and mental component score (MCS, 0-100 range) – higher is better, with a difference of 3 to 4 points considered clinically meaningful;

<sup>††</sup> VEINES overall score (0-100 range) and symptom specific score (0-100 range) – higher is better;

<sup>‡‡</sup> Mean change scores, SEs, and treatment differences estimated using multiple linear regression adjusted for center;

<sup>§§</sup> patient-reported severity of pain in the index leg (0-7 range) – higher is worse;

<sup>///</sup> leg circumference measured at 10cm below tibial tuberosity of the index leg.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript